Exhibit 99.1

FOR IMMEDIATE RELEASE

Contacts:

CryoLife	The Ruth Group
D. Ashley Lee	Tram Bui / Emma Poalillo
Executive Vice President, Chief Financial Officer and Chief Operating Officer	646-536-7035 / 7024 tbui@theruthgroup.com
Phone: 770-419-3355	epoalillo@theruthgroup.com

CryoLifeReports Fourth Quarter and Full Year 2017 Results

FourthQuarterand Recent Business Highlights:

· Achieved fourthquarter revenuesof $52.8million

· Achieved double digitrevenue growthon a percentage basisin BioGlue®, On-X, and tissue processing

· RecordedGAAP net lossof ($3.0) million, or ($0.09)per fully diluted common share;  Non-GAAP net incomeof $4.0million, or $0.11perfully diluted common share

· Completed acquisition of JOTEC

· Accelerated enrollment in BioGlue China and PerClot®clinical trials

ATLANTA, GA – (March7,  2018) – CryoLife, Inc. (NYSE: CRY),  a leading cardiacand vascular surgery company focused on aortic disease, announced today its financial results for the fourthquarter and full yearended December 31, 2017. 

Pat Mackin, Chairman, President, and Chief Executive Officer, said, “We had a solid fourth quarter capping off a tremendously successful year for CryoLife. In the fourth quarter, we generated double digit revenue growth in BioGlue, On-X and tissue processing.  We now sell direct in more countries than ever before with more geographies converting to direct sales shortly.As a result, we expanded our gross margin and, at the same time in the quarter,closedthe JOTEC acquisition andmade substantial progress on integration.Our On-Xdouble digit revenue growth was even more impressive in the face of temporarydisruptions in ordersresultingfrom going direct in Spain, Italy, and Poland.Importantly, On-X’s24 percent  year-over-yearfourth quarter performance in North America furthervalidates our direct sales strategy.”

Mr. Mackin added, “In addition to maximizing the value of our existing product portfolio, we believe we are well-positioned to drive future growth from products in development.We have enrolled over 100 patients in the BioGlue China clinical trial and accelerated enrollment in the PerClot FDA clinical trial, with both trials on track for potentialregulatory approval in the second half of 2019.Further, the acquisition of JOTEC brought us additional R&D expertise and an exciting and broad new product pipeline.If  these products are approved, they should be growth driversin the years to come.We also expect the combination of a 125 person sales force with our highly competitive products to drive strong performance in 2018 and beyond.”

“2017 was a transformational year for CryoLife.  We have never been more competitive than we are today, with a larger direct sales force and a larger addressable market opportunity, which positions us for years to come to accelerate significant growth and profitability,” Mr. Mackin concluded.  

Revenues for the fourthquarter of 2017 increased 17 percent to $52.8 million, compared to $45.0 million for the fourthquarter of 2016.  The increase was primarily driven by double digit revenue growth on a percentage basis in BioGlue,  On-X and tissue processing revenues, and$4.1 million in revenues from JOTEC for the month of December 2017.  Non-GAAP revenues for the fourth quarter of 2017 increased 8 percent compared to the fourth quarter of 2016.

Revenues for the full year of 2017 increased 5 percent to $189.7 million, compared to $180.4 million for the full yearof 2016.  The increase was primarily driven by increases in BioGlue,  On-Xand tissue processing revenues,  and revenues from JOTEC for the month of December 2017.  Non-GAAP revenues for the full yearof 2017increased 3 percent compared to the full yearof 2016.  A reconciliation of GAAP to non-GAAP financial metrics is included as part of this press release.

Net loss for the fourthquarter of 2017 was ($3.0) million, or ($0.09) per fully diluted common share, compared to net income of $2.9 million, or $0.09per fully diluted common share for the fourthquarter of 2016.  Non-GAAP net income for the fourthquarter of 2017 was $4.0million, or $0.11per fully diluted common share, compared to non-GAAP net income of $4.1million, or $0.12per fully diluted common share for the fourthquarter of 2016.

Net income for the full yearof 2017 was $3.7 million, or $0.11 per fully diluted common share, compared to net income of $10.8 million, or $0.32 per fully diluted common share for the full yearof 2016.  Non-GAAP net income for the full yearof 2017 was $13.8million, or $0.40per fully diluted common share, compared to non-GAAP net income of $16.0 million, or $0.48 per fully diluted common share for the full yearof 2016.

The Company is issuing itsfull year 2018 financial guidance, as summarized below:

2018Initial Financial Guidance Summary
Total Revenues	$250.0million - $256.0million
Gross Margins	65.5% - 66.5% (includes $3.5 million non-cash charges related to acquired JOTECinventory and distributor inventory buy backs)
R&D Expenses	$23.0 million - $25.0 million
Income Tax Rate	Mid 20% (excludes effect of nondeductible transaction costs and the tax effect of stock compensation expenses)
Non-GAAP EPS	$0.29- $0.32 (assumes approximately 37.5 million fully diluted shares outstanding and 25% effectivetax rate)

The Company also expects the following for the full year of 2018:

· Integration and related expenses of approximately $4.0 million

· Depreciation expense between $7.0 million and $8.0 million

· Amortization expense between $11.0 million and $12.0 million

Page 2 of 9

· Interest expense between $15.5 million and $16.0 million. 

All numbers in the table above are presented on a GAAP basis except where expressly referenced as non-GAAP.  The Company does not provide GAAP income per common share on a forward-looking basis because the Company is unable to predict with reasonable certainty business development and acquisition-related expenses, purchase accounting fair value adjustments, and any unusual gains and losses without unreasonable effort.  These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP.

The Company’s financial guidance for 2018is subject to the risks identified below.  

Non-GAAP Financial Measures

This press release contains non-GAAP financial measures.  Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with U.S. GAAP.  In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies.  The Company’s non-GAAP revenues include (as applicable) On-X revenues for the period in 2016 prior to the closing of the acquisition and excludes revenues for the HeRO® Graft and ProCol® product lines for 2016 and excludes JOTEC revenues for December 2017.  The Company’s other non-GAAP results exclude (as applicable) business development expenses; gain on sale of business components; amortization expenses; and inventory basis step-up expense.  The Company believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions and the operating expense structure of the Company’s existing and recently acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses and the transaction and integration expenses incurred in connection with recently acquired and divested product lines.  The Company believes it is useful to exclude certain expenses because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods as a result of factors such as acquisitions, or non-cash expense related to amortization of previously acquired tangible and intangible assets.   The Company does, however, expect to incur similar types of expenses in the future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur.

Webcast and Conference Call Information

The Company will hold a teleconference call and live webcast tomorrow, March 8, 2018 at 8:00 a.m. ET to discuss the results followed by a question and answer session hosted by Mr. Pat Mackin.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 8:00 a.m. ET.  A replay of the teleconference will be available through March15,and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415.  The conference number for the replay is 13676706.

Page 3 of 9

The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife website at www.cryolife.com and selecting the heading Webcasts & Presentations.

About CryoLife, Inc.

Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair.  CryoLife markets and sells products in more than 90 countries worldwide.  For additional information about CryoLife, visit our website, www.cryolife.com. 

Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements reflect the views of management at the time such statements are made.  These statements include our forecasted revenues, gross margins, R&D expenses, income tax rate and non-GAAP earnings per share; our forecasted integration and related expenses, depreciation expense, amortization expense and interest expense for 2018; our expectation that we will sell directly rather than through distributors in additional geographies and that this direct sales strategy is better than selling indirectly; our belief that we will maximize the value of our existing product portfolio and that we are well-positioned to drive future growth from our products in development; our belief that our BioGlue China clinical trialand our PerClot FDA clinical trial are on track for potential regulatory approval in the second half of 2019; our expectation that the JOTEC acquisition provides us with full and exciting new product pipeline and if these products are approved, they should be growth drivers in the years to come; our expectation that the combination of a 125 person direct sales force with our highly competitive products, will drive strong performance in 2018 and beyond;our expectation that 2017 will prove to be a transformational year; our belief that we have never been bettermore competitive than we are today, with a larger direct sales force and a larger addressable market opportunity, which positions us for years to come to accelerate significant growth and profitability. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for year ended December 31, 2016 and Forms 10-Q for periods ended March 31, 2017, June 30, 2017 and September 30, 2017. These risks and uncertainties also include that our beliefs regarding the benefits of the JOTEC acquisition, including that this acquisition provides us with product portfolios that are technologically and clinically differentiated and offer strong competitive advantages, substantially enhance our growth potential and ability to drive profitable growth, strengthen our direct sales force, significantly accelerates our going direct strategy, increase our cross-selling opportunities, and significantly enhance our R&D capabilities and pipelinemay be incorrect; our projections of markets sizes and revenue growth rates for our four product lines, clinical trial timelines and clearance or approval times for new products or new indications may be incorrect or may change over time. As with most acquisitions, the successful integration of JOTEC’s businesses with ours may take longer and prove more costly than expected, and we may experience currently unforeseen difficulties related to the JOTEC products and our combined sales forces’ ability to successfully market them.  If we experience problems that slow the integration of JOTEC's business with CryoLife’s business, we may not be able to secure the anticipated financial and operational benefits of the acquisition as soon as anticipated, or at all. 

Page 4 of 9

We may also inherit unforeseen risks and uncertainties related to JOTEC's business, particularly if the information received by CryoLife during the due diligence phase of this transaction is incomplete or inaccurate. Our plans with respect to the transaction’s financing could change based on currently unforeseen circumstances. CryoLife does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise.

Page 5 of 9

CRYOLIFE, INC. AND SUBSIDIARIES

Financial Highlights

(In thousands, except per share data)

	Three Months Ended				Twelve Months Ended
	December 31,				December 31,
	2017		2016		2017		2016
Revenues:
Products	$	35,112	$	28,925	$	119,631	$	113,992
Preservation services		17,714		16,104		70,071		66,388
Total revenues		52,826		45,029		189,702		180,380
Cost of products and preservation services:
Products		8,601		6,734		29,798		28,033
Preservation services		7,862		7,100		31,262		33,448
Total cost of products and
preservation services		16,463		13,834		61,060		61,481
Gross margin		36,363		31,195		128,642		118,899
Operating expenses:
General, administrative, and marketing		30,195		22,246		101,211		91,548
Research and development		6,363		3,844		19,461		13,446
Total operating expenses		36,558		26,090		120,672		104,994
Gain from sale of business components		--		--		--		(7,915)
Operating (loss) income		(195)		5,105		7,970		21,820
Interest expense		2,396		787		4,881		3,043
Interest income		(53)		(24)		(212)		(72)
Other (income) expense, net		(190)		583		(260)		437
(Loss) income before income taxes		(2,348)		3,759		3,561		18,412
Income tax expense (benefit)		659		862		(143)		7,634
Net (loss) income	$	(3,007)	$	2,897	$	3,704	$	10,778
(Loss) income per common share:
Basic	$	(.09)	$	.09	$	.11	$	.33
Diluted	$	(.09)	$	.09	$	.11	$	.32
Weighted-average common shares outstanding:
Basic		34,025		32,223		33,008		31,855
Diluted		34,025		33,443		34,163		32,822

Page 6 of 9

CRYOLIFE, INC. AND SUBSIDIARIES

Financial Highlights

(In thousands)

	Three Months Ended						Twelve Months Ended
	December 31,						December 31,
	2017			2016			2017				2016
Products:
BioGlue and BioFoam	$	17,845		$		15,982	$	37,041			$	63,461
On-X		9,993				9,073		65,939				34,232
CardioGenesis cardiac laser therapy		1,736				2,367		6,866				7,864
PerClot		892				1,038		3,533				4,021
PhotoFix		510				465		2,116				1,871
HeRO Graft		--				--		--				2,325
ProCol		--				--		--				218
JOTEC		4,136				--		4,136				--
Total products		35,112				28,925		119,631				113,992
Preservation services:
Cardiac tissue		8,599				7,442		32,510				29,697
Vascular tissue		9,115				8,662		37,561				36,691
Total preservation services		17,714				16,104		70,071				66,388
Total revenues	$	52,826		$		45,029	$	189,702			$	180,380
Revenues:
U.S.	$	34,648		$		32,885	$	135,102			$	131,727
International		18,178				12,144		54,600				48,653
Total revenues	$	52,826		$		45,029	$	189,702			$	180,380
			December 31,						December 31,
			2017						2016
Cash, cash equivalents, and restricted securities			$		40,753				$	57,341
Total current assets					179,280					147,233
Total assets					591,670					316,140
Total current liabilities					42,940					30,102
Total liabilities					312,635					107,157
Shareholders’ equity					279,035					208,983

Page 7 of 9

CRYOLIFE, INC. AND SUBSIDIARIES

Reconciliation of GAAP to Non-GAAP

Net Income and Diluted Income per Common Share

(In thousands, except per share data)

	Three Months Ended				Twelve Months Ended
	December 31,				December 31,
	2017		2016		2017		2016
GAAP:
(Loss) income before income taxes	$	(2,348)	$	3,759	$	3,561	$	18,412
Income tax expense (benefit)		659		862		(143)		7,634
Net(loss) income	$	(3,007)	$	2,897	$	3,704	$	10,778
Diluted (loss) incomeper common share:	$	(0.09)	$	0.09	$	0.11	$	0.32
Diluted weighted-average common
shares outstanding		34,025		33,443		34,163		32,822
Reconciliation of income before income
taxes, GAAP to net income, non-GAAP:
(Loss) income before income taxes, GAAP	$	(2,348)	$	3,759	$	3,561	$	18,412
Adjustments:
Business development expenses		6,555		832		10,935		7,880
Gain on sale of business components		--		--		--		(7,915)
Amortization expense		1,662		1,153		5,085		4,426
Acquisition inventory basis step-up expense		584		822		2,728		3,039
Income before income taxes, non-GAAP		6,453		6,566		22,309		25,842
Income tax expense calculated at 38% normalized
tax rate		2,452		2,495		8,477		9,820
Net income, non-GAAP	$	4,001	$	4,071	$	13,832	$	16,022
Reconciliation of diluted income per
common share, GAAP to diluted income per
common share, non-GAAP:
Diluted (loss) income per common share, GAAP:	$	(0.09)	$	0.09	$	0.11	$	0.32
Adjustments:
Business development expenses		0.19		0.02		0.31		0.24
Gain on sale of business components		--		--		--		(0.24)
Amortization expense		0.05		0.03		0.15		0.13
Acquisition inventory basis step-up expense		0.02		0.02		0.08		0.09
Tax effect of non-GAAP adjustments		(0.11)		(0.02)		(0.21)		(0.08)
Effect of 38% normalized tax rate		0.05		(0.02)		(0.04)		0.02
Diluted income per common share,
non-GAAP:	$	0.11	$	0.12	$	0.40	$	0.48
Diluted weighted-average common
shares outstanding		35,090		33,443		34,163		32,822

Page 8 of 9

CRYOLIFE, INC. AND SUBSIDIARIES

Reconciliation of GAAP to Non-GAAP

Revenues; Gross Margin; General, Administrative, and Marketing

(In thousands, except per share data)

	Three Months Ended					Twelve Months Ended
	December 31,					December 31,
	2017		2016		Growth Rate	2017		2016		Growth Rate
Reconciliation of total revenues, GAAP
to total revenues, non-GAAP:
Total revenues, GAAP	$	52,826	$	45,029	17%	$	189,702	$	180,380	5%
Plus: On-X pre acquisition revenues		--		--			--		1,627
Less: HeRO revenues		--		--			--		(2,325)
Less: ProCol revenues		--		--			--		(218)
Less: JOTEC revenues		(4,136)		--			(4,136)		--
Total revenues, non-GAAP	$	48,690	$	45,029	8%	$	185,566	$	179,464	3%
	Three Months Ended					Twelve Months Ended
	December 31,					December 31,
	2017		2016			2017		2016
Reconciliation of gross margin %,
GAAP to gross margin %,
non-GAAP:
Total revenues, GAAP	$	52,826	$	45,029		$	189,702	$	180,380
Gross margin, GAAP	$	36,363	$	31,195		$	128,642	$	118,899
Gross margin %, GAAP		69%		69%			68%		66%
Gross margin, GAAP	$	36,363	$	31,195		$	128,642	$	118,899
Plus: Acquisition inventory basis step-
up expense		584		822			2,728		3,039
Gross margin, non-GAAP	$	36,947	$	32,017		$	131,370	$	121,938
Gross margin %, non-GAAP		70%		71%			69%		68%
	Three Months Ended					Twelve Months Ended
	December 31,					December 31,
	2017		2016			2017		2016
Reconciliation of general,
administrative, and marketing,
expense, GAAP to general,
administrative, and marketing,
expense, non-GAAP
General, administrative, and marketing
expense, GAAP	$	30,195	$	22,246		$	101,212	$	91,548
Less: Business development
expenses		(6,555)		(832)			(10,935)		(7,880)
General, administrative, and
marketing expense,
non-GAAP	$	23,640	$	21,414		$	90,277	$	83,668

Page 9 of 9